Medical device polymer

• US 5,447,724 A
• Filed: 11/15/1993
• Issued: 09/05/1995
• Est. Priority Date: 05/17/1990
• Status: Expired due to Term

• Current Assignee: Harbor Medical Devices Incorporated
• Original Assignee: Harbor Medical Devices Incorporated
• Inventors: Helmus, Michael N., Tolkoff, M. Joshua, Raleigh, Carol L.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): AZPURU, CARLOS A
• Application Number:
  US08/152,876
• Time in Patent Office: 659 Days
• Field of Search: 424/423, 424/424, 424/425, 424/426, 424/486, 424/497, 424/450, 427/2, 514/822, 523/112, 523/113, 604/53, 604/266, 623/12
• US Class Current: 424/426
• CPC Class Codes: A61L 2300/22 Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
• CPC Class Codes: A61L 2300/222 Steroids, e.g. corticosteroids
• CPC Class Codes: A61L 2300/236 Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 33/0011 Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
• CPC Class Codes: A61L 33/0047 Enzymes, e.g. urokinase, streptokinase
• CPC Class Codes: A61L 33/007 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50
• CPC Class Codes: A61M 5/14276 specially adapted for implantation

Abstract

A medical device and a method for its manufacture. The function of the medical device requires exposure of the device to the tissue of a patient. The device has a tissue-exposed portion constructed to release an agent that inhibits adverse reaction to the presence of the device defined by a polymeric surface-layer overlying in a supported manner a polymer defining a reservoir. The reservoir incorporates the agent in a manner that permits substantially free outward release of the agent from the reservoir and the overlying layer defines metering outward passages constructed to control the outward migration of the agent to enable prolonged release of the agent from the surface of the medical device to prevent the adverse reaction due to the presence of the device.

Claims

1. A medical device at least a portion of which comprises:

a body insertable into a patient, said body having an exposed surface which is adapted for exposure to tissue of a patient and constructed to release, at a predetermined rate, a therapeutic agent adapted to inhibit adverse physiological reaction of said tissue to the presence of the body of said medical device,

said therapeutic agent selected from the group consisting of antithrombogenic agents, antiplatelet agents, prostaglandins, thrombolytic drugs, antiproliferative drugs, antirejection drugs, antimicrobial drugs, growth factors, and anticalcifying agents,

at said exposed surface, said body including;

an outer polymer metering layer, and

an internal polymer layer underlying and supporting said outer polymer metering layer and in intimate contact therewith, said internal polymer layer defining a reservoir for said therapeutic agent,

said reservoir formed by a polymer selected from the group consisting of polyurethanes and its copolymers, silicone and its copolymers, ethylene vinylacetate, thermoplastic elastomers, polyvinylchloride, polyolefins, cellulosics, polyamides, polytetrafluoroethylenes, polyesters, polycarbonates, polysulfones, acrylics, and acrylonitrile butadiene styrene copolymers,

said outer polymer metering layer having a stable, substantially uniform, predetermined thickness covering the underlying reservoir so that no portion of the reservoir is directly exposed to body fluids and incorporating a distribution of an elutable component which, upon exposure to body fluid, elutes from said outer polymer metering layer to form a predetermined porous network capable of exposing said therapeutic agent in said reservoir in said internal polymer layer to said body fluid,

said elutable component is selected from the group consisting of polyethylene oxide, polyethylene glycol, polyethylene oxide/polypropylene oxide copolymers, polyhydroxyethylmethacrylate, polyvinylpyrollidone, polyacrylamide and its copolymers, liposomes, albumin, dextran, proteins, peptides, polysaccharides, polylactides, polygalactides, polyanhydrides, polyorthoesters and their copolymers, and soluble cellulosics,

said reservoir defined by said internal polymer layer incorporating said therapeutic agent in a manner that permits substantially free outward release of said therapeutic agent from said reservoir into said porous network of said outer polymer metering layer as said elutable component elutes from said polymer metering layer, said predetermined thickness and the concentration and particle size of said elutable component being selected to enable said outer polymer metering layer to meter the rate of outward migration of the therapeutic agent from said internal reservoir layer through said outer polymer metering layer.

said outer polymer metering layer and said internal polymer layer, in combination, enabling prolonged controlled release, at said predetermined rate, of said therapeutic agent at an effective dosage level from said exposed surface of said body of said medical device to the tissue of said patient to inhibit adverse reaction of the patient to the prolonged presence of said body of said medical device in said patient.

2. The medical device of claim 1 wherein said reservoir is a coating less than about 100 mils thick.

3. The medical device of claim 1 wherein said reservoir is about 2 to 3 mils thick.

4. The medical device of claim 1 wherein said polymer metering layer is less than about 100 mils thick.

5. The medical device of claim 4 wherein said surface-layer is about 2 to 3 mils thick.

6. The medical device of claim 1 wherein said outer polymer metering surface-layer and internal polymer layer are constructed for prolonged release of the therapeutic agent for a period corresponding to the duration of said exposure of said body to said tissue.

7. The medical device of claim 1 wherein said outer polymer metering surface-layer and internal polymer layer are constructed for release at levels effective to inhibit adverse reaction of the patient to the presence of said body in said patient for at least about 200 hours.

8. The medical device of claims 1 or 7 wherein said reservoir includes more than about 30% by weight of said therapeutic agent.

9. The medical device of claim 8 wherein said reservoir includes about 40 to 60% by weight of said therapeutic agent.

10. The medical device of claim 1 wherein said reservoir includes a non-physiologically active elutable component.

11. The medical device of claim 1 wherein said antithrombogenic drug is heparin.

12. The medical device of claim 1 wherein said therapeutic agent is in particulate form with a particle size about the thickness of said reservoir or less.

13. The medical device of claim 12 wherein said therapeutic agent is of less than about 10 micron particle size.

14. The medical device of claim 1 wherein said outer polymer metering layer includes less than about 20% by weight of said elutable component.

15. The medical device of claim 14 wherein said outer polymer metering layer includes about 10 to 20% by weight of said elutable component.

16. The medical device of claim 1 wherein said elutable component comprises colloidal regions in said surface layer.

17. The medical device of claim 16 wherein said elutable component colloidal regions are polyethylene oxide.

18. The medical device of claim 17 wherein said polyethylene oxide has a molecular weight of less than about 100,000.

19. The medical device of claim 1 wherein said elutable component comprises particulate regions.

20. The medical device of claim 1 wherein said elutable component includes a physiologically active agent.

21. The medical device of claim 1 wherein said elutable component includes a minor amount of said physiologically active agent prior to exposure of said exposed surface to said tissue.

22. The medical device of claim 1 wherein said elutable components create regions of about 50 microns or less in said first polymer metering surface-layer.

23. The medical device of claim 22 wherein said elutable components create regions about 10 microns or less.

24. The medical device of claim 23 wherein said elutable components create submicron regions.

25. The medical device of claim 1 wherein said device is a blood oxygenator.

26. The medical device of claim 1 wherein said outer polymer metering surface-layer covers the entire exposed surface of said body and said internal polymer layer is coextensive with said outer polymer metering surface-layer.